New Zealand-based Rua Bioscience has a “positive future”, with sales in the first quarter of FY25 double that of the same period last year and expected to continue rising, the company has said.
The bullish outlook followed a worrying assessment by its auditor, PricewaterhouseCoopers (PWC), which said it was unable to obtain sufficient audit evidence to provide an opinion on Rua’s accounts.
It flagged a number of issues relating to the firm’s finances, including the subjective nature of future business performance and “key assumptions relating to expected future revenues and margins”.
Continue reading...
